An observational study in Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 27th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 500 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 59 across the 17 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice
The study population will consist of adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy that have received mavacamten treatment in China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Chinese guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy, i.e., satisfy criteria below:
Note:
* Essential baseline information, including age, gender, resting or provoked LVOT peak gradient, LVEF, indices of cardiac structure (e.g., maximum LV wall thickness, atrial and ventricular chamber size and volumes), as well as systolic and diastolic function, NYHA functional class.
Critical data, including resting or provoked LVOT gradient, LVEF, cardiac structure, systolic and diastolic function, dose of mavacamten.
Key follow-up time points: including weeks 4, 8, 12, 24, 36, 48, 72 and 96.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten
Drug: Mavacamten
According to the product label
Change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient
Time frame: Week 48, Week 96
Change from baseline in resting valsalva left ventricular outflow tract (LVOT) gradient
Time frame: Week 48, Week 96
Change from baseline in New York Heart Association (NYHA) class
Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, and Week 96
Number and proportion of participants with a resting/provoked left ventricular outflow tract (LVOT) gradient < 30/50 mmHg
Time frame: Week 12, Week 36, Week 48, Week 72, and Week 96
Number and proportion of participants achieving complete response (defined as all left ventricular outflow tract (LVOT) gradients < 30 mmHg and New York Heart Association (NYHA) Class I)
Time frame: Week 12, Week 36, Week 48, Week 72, and Week 96
Not enrolling at this site.
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →